Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay 26, 2015	Xencor to Present at Jefferies 2015 Healthcare Conference MONROVIA, Calif. , May 26, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , President and	View HTML Xencor to Present at Jefferies 2015 Healthcare Conference 15.3 KB
Toggle SummaryMay 13, 2015	Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory Affairs and Wayne Saville, M.D., as Vice President of Clinical Oncology MONROVIA, Calif. , May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Mark Lotz ,	View HTML Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory Affairs and Wayne Saville, M.D., as Vice President of Clinical Oncology 19.1 KB
Toggle SummaryMay 11, 2015	Xencor's XmAb®5871 Program to be Featured in Poster Presentation at European League Against Rheumatism (EULAR) 2015 Annual Meeting MONROVIA, Calif. , May 11, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that data from the Phase 1b/2a	View HTML Xencor's XmAb®5871 Program to be Featured in Poster Presentation at European League Against Rheumatism (EULAR) 2015 Annual Meeting 69.5 KB
Toggle SummaryMay 04, 2015	Xencor Reports First Quarter 2015 Financial and Operating Results MONROVIA, Calif. , May 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the first	View HTML Xencor Reports First Quarter 2015 Financial and Operating Results 31.5 KB
Toggle SummaryApr 29, 2015	Xencor to Webcast Presentations at Two Upcoming Conferences in May MONROVIA, Calif. , April 29, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced it will webcast presentations by	View HTML Xencor to Webcast Presentations at Two Upcoming Conferences in May 16 KB
Toggle SummaryApr 28, 2015	Xencor to Host First Quarter 2015 Financial Results Webcast and Conference Call on May 4, 2015 MONROVIA, Calif. , April 28, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter 2015	View HTML Xencor to Host First Quarter 2015 Financial Results Webcast and Conference Call on May 4, 2015 15.9 KB
Toggle SummaryMar 19, 2015	Xencor Appoints A. Bruce Montgomery, M.D. to Board of Directors MONROVIA, Calif. , March 19, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of A.	View HTML Xencor Appoints A. Bruce Montgomery, M.D. to Board of Directors 17.2 KB
Toggle SummaryMar 16, 2015	Xencor to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference MONROVIA, Calif. , March 16, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that John Kuch , Vice President	View HTML Xencor to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference 15.8 KB
Toggle SummaryMar 02, 2015	Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock MONROVIA, Calif. , March 2, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the completion of an underwritten public offering of 8,625,000 shares of its common stock, including 1,125,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters	View HTML Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock 17.3 KB
Toggle SummaryFeb 25, 2015	Xencor, Inc. Prices Public Offering of Common Stock MONROVIA, Calif. , Feb. 25, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock, offered at a price to the public of $14.25 per share. The gross proceeds from this offering to Xencor are expected to	View HTML Xencor, Inc. Prices Public Offering of Common Stock 16 KB

Tools

Press Releases